Objective -To determine the influence of IL-1 on the presence and the distribution of tenascin in matrix of human normal and osteoarthritic cartilage explants. Methods -Cartilage was grown in organotypic culture with or without IL-1I (10 ng ml'). Tenascin antigen was detected on cryopreserved cartilage sections by immunohistochemical techniques with a monoclonal antibody directed against all tenascin isoforms (BC-4), and then quantified by video imaging densitometry.
Interleukin-1 (IL-1) has been implicated in degradation of the extracellular matrix of cartilage during the osteoarthritic process through an increase in the expression of metalloproteinases. ' In osteoarthritis, a decrease in the content of normal cartilage components is associated with an accumulation of adhesive glycoproteins such as fibronectins' and tenascin. 3 Tenascin is a large extracellular matrix glycoprotein (1.900 kDa), comprising six similar subunits.5 Each subunit contains epidermal growth factor-like (EGF-L) repeats and Fn type III homology repeats, and a domain showing sequence similarities with fibrinogen.5 Tenascin has been isolated from various tissues undergoing remodelling."
Factors that influence the accumulation of tenascin in osteoarthritic cartilage are unknown. The purpose of this study was to determine whether tenascin distribution in normal and osteoarthritic cartilage can be influenced by IL-1.
Methods

AMATERIALS
All materials, unless otherwise specified were from Sigma (St Louis, MO, USA). OCT was from Miles (Napierville, IL, USA). Recombinant human ILl P was from Tebu Co (Paris, France). Alkaline phosphatase conjugated streptavidin-biotin complex was from Dako (Paris, France). Testicular hyaluronidase was from Serve (Heidelberg, Germany). Dishes for explant cultures were from Falcon (USA). Material for electrophoresis was from Biorad SA (Paris, France).
MONOCLONAL ANTIBODIES
A specific monoclonal (MAb) antibody (BC-4) against human tenascin was used to study the distribution of tenascin in cartilage.9 HUMAN fig 1) . First, the number of chondrocytes immunoreactive for tenascin was only slightly higher in osteoarthritic cartilage (68% of positive cells in osteoarthritis v 62% in normal cartilage). Second, the intensity (pericellular area) and the matrix scores were higher in osteoarthritic than in normal cartilage, whatever the layer (fig 1, fig 3) . Third, in osteoarthritic cartilage there was intense staining on the cartilage surface in contact with synovial fluid.
PRESENCE OF TENASCIN IN NORMAL AND OSTEO-ARTHRITIC CARTILAGE EXPLANTS: INFLUENCE OF
IL-1:3 (10 ng ml-') In normal cartilage, treatment with IL-1f induced an increase in the number of positive cells as well as an increase in the intensity of pericellular staining (intensity score). Similarly, but to a lesser degree, IL-1 induced a four-to fivefold increase in the matrix score.
In osteoarthritic cartilage the number of immunoreactive chondrocytes did not increase significantly, but the intensity of staining increased in the pericellular area and in the interterritorial matrix (figs 2 and 3). This was mostly due to enhanced staining in the superficial layer.
When comparing normal and osteoarthritic cartilage, the effect of IL-1 appeared more pronounced in normal cartilage. In the superficial layer the intensity score increased threefold in normal cartilage and only 1.6-fold in osteoarthritic cartilage. Similarly, the matrix score in the superficial layer increased of fourfold in normal cartilage and only twofold in osteoarthritic cartilage.
Otherwise distribution of tenascin was not strictly correlated to the proteoglycan loss. 
Discussion
The main result of this study is to show that IL-i1 induces an increase in tenascin content in both normal and osteoarthritis cartilage. We used an automated computerised technique which is a valid method to quantify tenascin because the staining appeared as a distinct structure on a colourless background. This technique would not be effective for other macromolecules with diffuse distribution, such as collagen or fibronectin.
The effect of IL-13 was more pronounced in normal than in osteoarthritic cartilage.
Tenascin intensity score in IL-i 3 treated normal cartilage was close to the level observed in osteoarthritic cartilage, suggesting that IL-1 might contribute to the accumulation of tenascin in damaged cartilage. In osteoarthritic cartilage, tenascin diffusion from synovial fluid may account for the observed staining, notably on the cartilage surface.3 Under IL-1 stimulation there is an increased staining intensity in both the pericellular zone and its contingent interterritorial matrix, suggesting that the presence of tenascin in matrix distant from the chondrocyte may be due to a continuous increase in the production of tenascin by the chondrocyte. 
